Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).
Mai EK, et al. Among authors: sauer s.
Leukemia. 2021 Mar;35(3):809-822. doi: 10.1038/s41375-020-0976-9. Epub 2020 Jul 20.
Leukemia. 2021.
PMID: 32684633
Free PMC article.
Clinical Trial.